PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
Format: Artigo
Sprache:Inglês
Veröffentlicht: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Schriftenreihe:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Schlagworte:
dabigatran etexelate
warfarin
vitamin k antagonists
atrial fibrillation
pharmacoecomomics
clinic-economic evaluation
cost-effectiveness
markov modeling
Online Zugang:https://www.rpcardio.com/jour/article/view/397
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Wird geladen...

Ähnliche Einträge